Nobilon acquires rights to EBx cell lines from Vivalis for development, production and marketing of influenza vaccines
Advertisement
Nobilon and Vivalis announced that Nobilon (part of Organon, the human healthcare business unit of Akzo Nobel) has acquired rights from Vivalis to its EBx® cell lines (derived from avian embryonic stem cells) and related technology platform for the development, production and marketing of human influenza vaccines, including seasonal and pandemic.
The licence is world-wide and non-exclusive. The financial terms of the agreement, which remain confidential, include an upfront payment, milestone payments and royalties.